Vivek Ra­maswamy's 'van­t' brain­chil­dren keep bear­ing fruit with Urovan­t's FDA nod for in­con­ti­nence med vibegron

Christ­mas has come ear­ly for Urovant Sci­ences as the for­mer Vivek Ra­maswamy out­fit scored an FDA ap­proval for its lead pro­gram.

The biotech’s over­ac­tive blad­der can­di­date vibegron will be the newest drug to hit the mar­ket, the agency said Wednes­day, giv­ing Urovant its first ap­proved prod­uct. Vibegron, a be­ta-3 ag­o­nist that’s tak­en as a once-dai­ly pill, will be sold as Gemte­sa. The drug is like­ly to launch in ear­ly 2021, CEO James Robin­son has pre­vi­ous­ly said.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.